ANCA-Associated Vasculitis Drug Pipeline — PatSnap Eureka
ANCA-Associated Vasculitis Drug Pipeline: Complement, B Cell & Plasma Cell Targeting
The AAV field is shifting from broad immunosuppression to precision targeting of complement receptors, B cell surface markers, and plasma cell survival factors. Explore patent and literature signals across 9 therapeutic modalities — from avacopan to CAAR-T cell therapy — powered by PatSnap Eureka.
Nine Approaches Targeting the AAV Disease Mechanism
From oral small molecules to CAAR-T cell therapy, the ANCA-associated vasculitis pipeline spans complement inhibition, B cell depletion, plasma cell targeting, and antigen-specific tolerance induction — each addressing a distinct node in AAV pathology.
C5aR Antagonism — Avacopan (ChemoCentryx)
Avacopan (CCX168) blocks the C5a receptor such that plasma levels of complement factors Bb, C3a, and C5a do not significantly change upon treatment — distinguishing it from upstream C5 inhibition. The ADVOCATE randomized controlled trial evaluated avacopan 30 mg twice daily versus tapering prednisone in AAV patients receiving background cyclophosphamide/azathioprine or rituximab. ChemoCentryx holds 10+ patent records across AU, CA, IL, JP, MX, TW, US, and WO.
Clinical RCT EvidenceAnti-CD20 B Cell Depletion — Rituximab (Genentech/Roche)
Genentech holds approximately 14 patent records covering methods of treating AAV by administering CD20-targeting antagonists at doses of approximately 400 mg to 1.3 grams, delivered as 1–3 doses within approximately one month. The RAVE trial (197 patients) provides clinical safety data identifying PR3-ANCA positivity and pulmonary hemorrhage as VTE risk factors. Jurisdictions include WO, EP, US, AU, SG, NO, JP, IN, ZA, HK, BR, and TW.
RAVE Trial ReferencedBLyS/APRIL Blockade — TACI-Fc (Rongchang Biopharmaceutical)
A TACI-Fc fusion protein from Rongchang Biopharmaceutical targets both BLyS (BAFF) and APRIL simultaneously — cytokines mediating B cell and plasma cell survival. This addresses long-lived plasma cells that are CD20-negative and may maintain persistent ANCA titers after anti-CD20 therapy. Patent text states the approach "exhibits good safety and therapeutic effects in the process of treating or alleviating patients with ANCA-associated vasculitis."
Plasma Cell TargetingDPP1 Inhibition — INS1007 (Insmed)
Insmed's INS1007 — the compound (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide — inhibits DPP1 (cathepsin C), a lysosomal cysteine protease required for activation of neutrophil serine proteases including PR3 and neutrophil elastase during neutrophil maturation. Patents filed across US, CA, AU, and JP cover GPA, MPA, and idiopathic crescentic glomerulonephritis.
Upstream Neutrophil BiologyCAAR-T Cell Therapy — PR3 (Juno Therapeutics / BMS)
Juno Therapeutics engineers T cells to express a chimeric receptor containing a PR3 antigen-binding domain, enabling selective elimination of anti-PR3 ANCA-producing B cells and plasma cells. Seven defined ANCA-binding epitopes on PR3 are disclosed (ANCA1–ANCA7), including MAHRPPSPAL, AQPHSRPYMAS, and PGSHFCGG. PR3 is the dominant ANCA autoantigen in approximately 90% of cANCA-positive GPA patients. One 2024 CN pending record.
Antigen-Specific PrecisionAntigen-Specific Tolerance — pMHCII Nanoparticles (UTI)
UTI Limited Partnership's nanoparticle platform displays peptide-MHC class II complexes to expand antigen-specific TR1 regulatory cells and tolerogenic B cells. AAV-relevant antigens explicitly listed include MPO506-520, MPO302-316, MPO721, MPO689-703, and PRTN3-derived peptides. The patent family spans WO, EP, CA, AU, SG, HK, CN, NZ, KR, and US — the broadest geographic spread of any platform in this dataset.
Immune Tolerance ResetTwo Principal Mechanisms Drive AAV Pathology
Retrieved results consistently identify two principal molecular mechanisms driving AAV pathology. First, primed neutrophils interact with ANCAs to release factors that activate the alternative complement pathway, initiating an amplification loop sustaining necrotizing inflammation during flares. Second, circulating B cells and plasma cells serve as the cellular source of ANCA production — a retrieved academic paper from Brigham and Women's Hospital/Harvard Medical School explicitly reports associations between circulating B cells, plasma cells, and regulatory T cells (Treg) with ANCA titers in AAV patients.
The C5a receptor (C5aR/CD88) is the dominant complement target addressed across multiple ChemoCentryx patents. A novel approach from Q32 Bio targets C3d and complement factor H — a fusion protein construct anchoring complement regulation locally at sites of C3d deposition rather than systemically depleting complement. An anti-C2 antibody approach from the University of Pennsylvania represents yet another complement node under investigation.
On the autoantibody side, PR3 (PRTN3) is targeted by CAAR-T cells (Juno Therapeutics), DPP1 inhibition upstream (Insmed), extracorporeal PR3 matrix devices (Gambro Lundia), and antigen-specific tolerance nanoparticles (UTI). MPO-ANCA disease — associated predominantly with MPA and EGPA — is addressed by tolerance nanoparticles (UTI), glycomodified decoy polypeptides (GlycoEra AG), and CCR8 biomarker research. Learn more about PatSnap's life sciences intelligence platform for tracking emerging autoimmune targets.
A novel diagnostic marker — the CD19+CD38+CD27−CD24+ B cell subset — is proposed in a recent Chinese patent filing from Beijing Hospital as a biomarker capable of differentiating AAV from membranous nephropathy and lupus nephritis, signaling emerging companion diagnostic development alongside therapeutics.
Pipeline Intelligence: Patent Activity & Development Stage
Visual analysis of the AAV patent dataset derived from PatSnap Eureka, illustrating assignee activity concentration and the distribution of therapeutic approaches by development stage.
Top AAV Patent Assignees by Record Count
Genentech/Roche (~14 records) and ChemoCentryx (10+) dominate the dataset; emerging entrants Q32 Bio, GlycoEra, and Juno Therapeutics signal new competitive activity from 2024–2026.
AAV Pipeline by Development Stage
2 of 9 modalities have clinical evidence (avacopan ADVOCATE trial, rituximab RAVE trial); 4 are preclinical or early IND-enabling; 3 represent device/platform stage approaches.
AAV Pathology Cascade & Intervention Points
Each therapeutic modality intervenes at a distinct node in the ANCA-neutrophil-complement amplification loop — from upstream DPP1 inhibition to downstream complement blockade and direct ANCA neutralization.
Who Holds the AAV Drug Pipeline IP?
Patent-driven innovation dominates this dataset. Academic literature provides mechanistic and clinical validation while commercial assignees consolidate IP across jurisdictions.
Monitor Competitor Patent Activity in AAV
Set up real-time alerts for new filings from ChemoCentryx, Q32 Bio, Juno Therapeutics, and emerging entrants — all within PatSnap Eureka.
Four Key Strategic Signals from the AAV Pipeline Dataset
Derived from patent claim analysis and clinical translational signals in the PatSnap Eureka dataset. These signals reflect innovation patterns observed across retrieved records only.
Complement Pathway IP Is the Most Active Commercial Battleground
ChemoCentryx's avacopan/C5aR antagonist portfolio spans 10+ jurisdictions with active or pending status in multiple markets. Q32 Bio's 2025 C3d/factor H fusion protein filings signal that the complement axis will attract additional entrants targeting novel nodes beyond C5aR. Organizations entering complement space must design around the dense avacopan IP perimeter, particularly around dosing regimen claims and urinary sCD163 patient stratification methods.
Anti-CD20 IP Is Largely Lapsed — But Companion Diagnostic IP Remains Active
The Genentech vasculitis method patent family is predominantly inactive, consistent with rituximab's biosimilar era. However, the Roche biomarker patent for B cell antagonist response prediction remains active (HK), and next-generation anti-CD20 formats (subcutaneous, fixed-dose) could revive method claim protection. The ChemoCentryx urinary sCD163 biomarker patent collectively signals an industry trend toward companion diagnostic development alongside therapeutics in AAV.
Beyond Monotherapy: Combination Strategies Emerging in AAV
The ADVOCATE trial protocol — avacopan combined with cyclophosphamide/azathioprine or rituximab as background therapy — establishes complement C5aR antagonism as an additive intervention to B cell depletion and conventional immunosuppression rather than a monotherapy replacement. ChemoCentryx patent language on urinary sCD163 biomarker-guided patient selection further suggests movement toward precision combination strategies based on individual patient complement activation status.
The co-existence of anti-CD20 (Genentech) and BLyS/APRIL blockade (Rongchang TACI-Fc) strategies in the dataset suggests that combination approaches addressing both CD20+ B cells and CD20-negative long-lived plasma cells may be pursued. This is consistent with the Harvard/BWH academic paper's finding that circulating plasma cells — which are CD20-negative — correlate with ANCA titers. According to NIH/PubMed AAV research, plasma cell persistence after anti-CD20 therapy remains a key driver of relapse.
Both the GlycoEra glycomodified polypeptide decoy approach and the Gambro Lundia extracorporeal PR3 matrix device represent strategies to physically reduce circulating ANCA burden — an emerging direction distinct from blocking ANCA production. These approaches may complement B cell and plasma cell depletion strategies by rapidly reducing pathogenic antibody levels during acute flares. The Vasculitis Foundation and EULAR continue to track combination regimen outcomes in AAV clinical practice guidelines.
For researchers tracking these developments, PatSnap's life sciences drug discovery platform enables landscape mapping across all combination patent claims. The PatSnap customer case studies demonstrate how biopharma teams use Eureka to identify white space in competitive therapeutic areas.
ANCA-Associated Vasculitis Drug Pipeline — key questions answered
AAV is a group of severe autoimmune small-vessel vasculitides — encompassing granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA) — driven by pathogenic autoantibodies targeting myeloperoxidase (MPO) and proteinase 3 (PR3). A shared hallmark is pauci-immune necrotizing and crescentic glomerulonephritis.
Avacopan (formerly CCX168) is an oral small molecule developed by ChemoCentryx that blocks C5aR (complement fragment 5a receptor). Unlike upstream C5 inhibitors, avacopan treatment does not significantly change plasma levels of complement factors Bb, C3a, and C5a — distinguishing it as a more targeted approach. The ADVOCATE randomized controlled trial evaluated avacopan 30 mg twice daily versus tapering oral prednisone in AAV patients receiving background cyclophosphamide/azathioprine or rituximab.
Anti-CD20 approaches do not address long-lived ANCA-producing plasma cells, which are CD20-negative. Academic literature from Harvard/Brigham and Women's Hospital directly associates circulating plasma cells with ANCA titers in AAV patients. The TACI-Fc approach (Rongchang Biopharmaceutical) targets both BLyS (BAFF) and APRIL — cytokines mediating plasma cell survival — representing the only plasma cell-directed asset identified in this dataset and addressing a meaningful clinical unmet need.
CAAR-T (chimeric autoantibody receptor T cell) therapy, developed by Juno Therapeutics (a Bristol Myers Squibb company), engineers T cells to express a chimeric receptor containing a PR3 antigen-binding domain, enabling selective elimination of anti-PR3 ANCA-producing B cells and plasma cells. The patent identifies seven defined ANCA-binding epitopes on PR3 (ANCA1–ANCA7). PR3 is the dominant ANCA autoantigen in approximately 90% of cANCA-positive GPA patients.
DPP1 (dipeptidyl peptidase 1, also called cathepsin C) is a lysosomal cysteine protease required for activation of neutrophil serine proteases including PR3 and neutrophil elastase during neutrophil maturation. Insmed's INS1007 inhibits DPP1 upstream of ANCA-neutrophil interaction, preventing the activation of pro-inflammatory proteases implicated in ANCA-driven tissue injury. This is the only small molecule approach in the dataset that acts at the level of neutrophil biology rather than autoantibody production or complement.
ChemoCentryx, Inc. is the most active single assignee in the AAV therapeutic space within this dataset, with at least 10 retrieved patent records across AU, CA, IL, JP, MX, TW, US, and WO jurisdictions for avacopan/C5aR antagonism. Genentech/Roche holds approximately 14 records for anti-CD20 methods across 12+ jurisdictions. Other active assignees include Insmed Incorporated (DPP1 inhibitor, multiple jurisdictions), UTI Limited Partnership (pMHCII nanoparticles, 10+ jurisdictions), Q32 Bio Inc. (C3d fusion protein, 2025 filings), and Juno Therapeutics (CAAR-T cells, CN pending).
Still have questions about the AAV pipeline? Let PatSnap Eureka search the patent and literature evidence for you.
Ask PatSnap Eureka About AAVAccelerate Your AAV Drug Discovery Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map complement, B cell, and plasma cell targeting IP — and identify white space in the ANCA-associated vasculitis pipeline.
References
- Dosing and Effect of C5A Antagonist with ANCA-Associated Vasculitis — ChemoCentryx, Inc., 2019, CA [Patent]
- C5aR Inhibitor Reduction of Urinary sCD163 — ChemoCentryx, Inc., 2019, WO [Patent]
- Journal Club Review of "Avacopan for the Treatment of ANCA-Associated Vasculitis" — University of California, San Francisco, 2022 [Paper]
- Method for Treating Vasculitis — Genentech, Inc., 2006, WO [Patent]
- Method for Treating Vasculitis — Genentech, Inc., 2007, US [Patent]
- Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in AAV — Massachusetts General Hospital/Harvard Medical School, 2019 [Paper]
- Method for Treating ANCA-Associated Vasculitis Using TACI-Fc Fusion Protein — Rongchang Biopharmaceutical (Shandong) Co., Ltd., 2025, TW [Patent]
- Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides for Treating ANCA Associated Vasculitides — Insmed Incorporated, 2019, CA [Patent]
- Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides for Treating Granulomatosis with Polyangiitis — Insmed Incorporated, 2019, US [Patent]
- Proteinase 3 (PR3) Chimeric Autoantibody Receptor T Cells and Related Methods and Uses — Juno Therapeutics, Inc., 2024, CN [Patent]
- Treatment of ANCA-Associated Vasculitis — Q32 Bio Inc., 2025, WO [Patent]
- Treatment of ANCA-Associated Vasculitis — Q32 Bio Inc., 2025, TW [Patent]
- Nanoparticle Compositions for Sustained Therapy — UTI Limited Partnership, 2025, EP [Patent]
- Glycomodified Polypeptides Targeting Anti-Neutrophil Autoantibodies and Uses Thereof — GlycoEra AG, 2026, JP [Patent]
- Extracorporeal Devices for Methods for Treating Diseases Associated with Anti-Neutrophil Cytoplasmic Antibodies — Gambro Lundia AB, 2020, WO [Patent]
- Vasculitis Foundation — ANCA-Associated Vasculitis Resources
- EULAR — European Alliance of Associations for Rheumatology: AAV Guidelines
- NIH/PubMed — ANCA-Associated Vasculitis Clinical Literature
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This page is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.